| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The active payload, MMAE, targets tubulin. MMAE binds tubulin and inhibits polymerization, disrupting microtubule dynamics, mitotic spindle formation, and cell division, leading to G2/M arrest and apoptosis. The linker is designed for cathepsin B–mediated release in the lysosome.
|
|---|---|
| ln Vitro |
MMAE inhibits tubulin polymerization and exhibits potent cytotoxicity against cancer cell lines, with IC50 values in the sub-nanomolar to low-nanomolar range. The linker-payload is inactive until cleaved; cathepsin B cleavage releases MMAE, which then exerts its cytotoxic effect.
|
| ln Vivo |
In ADC constructs, Ac-Lys-Val-Cit-PABC-MMAE delivers MMAE to target cells, producing potent antitumor activity in xenograft models with reduced systemic toxicity compared with free MMAE.
|
| Enzyme Assay |
Cathepsin B cleavage is measured by incubating the linker-payload with recombinant cathepsin B; released MMAE is quantified by LC-MS, and cleavage kinetics are derived. Tubulin polymerization inhibition by released MMAE is measured by turbidity assay.
|
| Cell Assay |
Target cells are treated with the ADC containing Ac-Lys-Val-Cit-PABC-MMAE; viability is measured by CellTiter-Glo, and mitotic arrest is assessed by flow cytometry or immunoblotting of phospho-histone H3. Cathepsin B dependence is confirmed using inhibitors or knockout cells.
|
| Animal Protocol |
Animals bearing target-positive tumors receive the ADC by intravenous injection; tumor growth is monitored, and intratumoral MMAE release is measured by LC-MS. Plasma stability of the ADC and systemic exposure to free MMAE are assessed by LC-MS/MS.
|
| References |
| Molecular Formula |
C66H108N12O14
|
|---|---|
| Molecular Weight |
1293.63573741913
|
| Exact Mass |
1292.81
|
| CAS # |
1650569-89-3
|
| Related CAS # |
Ac-Lys-Val-Cit-PABC-MMAE formic
|
| PubChem CID |
164886613
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.1
|
| tPSA |
365
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
39
|
| Heavy Atom Count |
92
|
| Complexity |
2350
|
| Defined Atom Stereocenter Count |
13
|
| SMILES |
O(C)[C@H]([C@H](C(N[C@H](C)[C@H](C1C=CC=CC=1)O)=O)C)[C@@H]1CCCN1C(C[C@H]([C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C(=O)OCC1C=CC(=CC=1)NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC([C@H](CCCCN)NC(C)=O)=O)=O)=O)C)=O)=O)OC)=O
|
| InChi Key |
KCGMOXVVJSQNOS-IZNBURIHSA-N
|
| InChi Code |
InChI=1S/C66H108N12O14/c1-16-41(8)56(51(90-14)36-52(80)78-35-23-28-50(78)58(91-15)42(9)59(82)70-43(10)57(81)46-24-18-17-19-25-46)76(12)64(87)54(39(4)5)75-63(86)55(40(6)7)77(13)66(89)92-37-45-29-31-47(32-30-45)72-60(83)49(27-22-34-69-65(68)88)73-62(85)53(38(2)3)74-61(84)48(71-44(11)79)26-20-21-33-67/h17-19,24-25,29-32,38-43,48-51,53-58,81H,16,20-23,26-28,33-37,67H2,1-15H3,(H,70,82)(H,71,79)(H,72,83)(H,73,85)(H,74,84)(H,75,86)(H3,68,69,88)/t41-,42+,43+,48-,49-,50-,51+,53-,54-,55-,56-,57+,58+/m0/s1
|
| Chemical Name |
[4-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-6-aminohexanoyl]amino]-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 200 mg/mL (~154.60 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7730 mL | 3.8651 mL | 7.7301 mL | |
| 5 mM | 0.1546 mL | 0.7730 mL | 1.5460 mL | |
| 10 mM | 0.0773 mL | 0.3865 mL | 0.7730 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.